Staar Surgical Co (Staar Surgical Co) GF Value : $88.90 (As of May. 07, 2024)

View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-07), Staar Surgical Co's share price is $45.94. Staar Surgical Co's GF Value is $88.90. Therefore, Staar Surgical Co's Price-to-GF-Value for today is 0.52.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Staar Surgical Co is Significantly Undervalued.

Staar Surgical Co (NAS:STAA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Staar Surgical Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	45.94	/	88.90
	=	0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Staar Surgical Co GF Value Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Staar Surgical Co (Staar Surgical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

SR3:Germany SR3:Germany

Address

25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630

Website

https://www.staar.com

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.

Executives

Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust	officer: Chief Operating Officer	17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna	officer: Chief Clinical, Regulatory,	C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday	officer: V.P., Research & Development	1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme	officer: Senior VP, Operations	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese	officer: VP, Global Marketing	1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason	director	2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten	officer: VP, General Counsel	1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams	officer: Chief Financial Officer	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer	officer: VP, International Marketing	1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman	director
Graydon C. Hansen	officer: Sr. VP, Global Operations	25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida	officer: VP, Global Clinical, Medical	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630